Pulsed Dye Laser (PDL) vs. Microsecond 1064-nm Nd:YAG Laser for Treatment of Diffuse Facial Redness

Sponsor
Northwestern University (Other)
Overall Status
Completed
CT.gov ID
NCT01529996
Collaborator
(none)
16
1
2
7
2.3

Study Details

Study Description

Brief Summary

The primary objective of this study is to compare the efficacy of PDL and the 1064-nm Nd:YAG laser in the treatment of facial redness.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Pulse Dye Laser/YAG laser
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
16 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Comparison of the Efficacy Between Pulsed Dye Laser (PDL) and the Microsecond 1064-nm Nd:YAG Laser for Treatment of Diffuse Facial Redness: A Pilot, Prospective Randomized Trial.
Study Start Date :
Jan 1, 2012
Actual Primary Completion Date :
Aug 1, 2012
Actual Study Completion Date :
Aug 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: YAG laser

Procedure: Pulse Dye Laser/YAG laser
This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.

Active Comparator: Pulse Dye Laer

Procedure: Pulse Dye Laser/YAG laser
This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.

Outcome Measures

Primary Outcome Measures

  1. Rating on global improvement scale [four months]

    Non-treating dermatologists will rate each side of the face using a global improvement scale to evaluate the effectiveness of the two treatments.

  2. Spectrophotometer measurement [four months]

    Spectrophotometer measurement as the percent resolution on each follow up visit compared to baseline visit

Secondary Outcome Measures

  1. Patient satisfaction [four months]

    Patients will record satisfaction on the questionnaires provided

  2. Recorded discomfort [four months]

    Subjects will record discomfort using a 10-point scale

  3. Adverse events [four months]

    Any adverse events will be recorded

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy patients 18-55 years of age with erythematotelangiectatic rosacea (as verified by the the PI).

  • Subjects who are willing to provide informed consent for participation in the study.

Exclusion Criteria:
  • Pregnant or lactating individuals

  • Subjects who are unable to understand the protocol or to give informed consent.

  • Subjects who have a known history of photosensitive conditions (e.g. Systemic lupus, polymorphous light eruption)

  • Subjects who have facial telangiectasia of diameter greater than 2 mm.

  • Subject who have significant (as determined by the PI) acute inflammatory papules, pustules, and vesicle involving the central face.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Northwestern University Feinberg School of Medicine, Department of Dermatology Chicago Illinois United States 60611

Sponsors and Collaborators

  • Northwestern University

Investigators

  • Principal Investigator: Murad Alam, MD, Northwestern University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Murad Alam, Professor in Dermatology, Otolaryngology - Head and Neck Surgery, and Surgery-Organ Transplantation, Northwestern University
ClinicalTrials.gov Identifier:
NCT01529996
Other Study ID Numbers:
  • STU55489
First Posted:
Feb 9, 2012
Last Update Posted:
Dec 2, 2021
Last Verified:
Nov 1, 2021
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 2, 2021